small molecule

XOFLUZA

BALOXAVIR MARBOXIL

Loss of exclusivityApril 2041latest FDA-listed patent expiry

CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand name	XOFLUZA
Active ingredient	BALOXAVIR MARBOXIL
Strength	2MG/ML
Dosage form	FOR SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	November 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
11925648	April 2041	product
11261198	September 2038	product
11306106	August 2037	use U-3000
10759814	August 2037	substance, product
10392406	April 2036	substance
10633397	April 2036	use U-3000
8987441	October 2032	substance, product
8927710	May 2031	product
9815835	June 2030	product

Regulatory exclusivity

Code	Expires
M-187	December 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Genentech